US equities |
NVDA $238.30 ▲+1.86% SPCX $167.65 ▲+5.47% MU $1,063.16 ▼-1.09% TSLA $379.76 ▲+2.47% MSFT $525.17 ▲+1.48% SNDK $1,711.28 ▼-0.51% INTC $117.10 ▼-1.87% META $743.32 ▲+2.09%
FinancialContent

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.040 +0.005 (+0.48%)
Delayed Quote Updated: 2:24 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Why Shares of Pliant Therapeutics Are Rising Tuesday ↗
The company's lead therapy fared well in a phase 2a trial to treat two separate conditions. 
Via The Motley Fool
News headline image
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Pre-market stock movers are among the biggest topics worth checking out on Tuesday and we have the latest news for investors! 
Via InvestorPlace
News headline image
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Expert Ratings for Pliant Therapeutics ↗
 
Via Benzinga
News headline image
Where Pliant Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Expert Ratings for Pliant Therapeutics ↗
 
Via Benzinga
News headline image
Recap: Pliant Therapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
What 12 Analyst Ratings Have To Say About Pliant Therapeutics ↗
 
Via Benzinga
News headline image
Pliant Therapeutics Shares Fall After Long-Term Data Of Bexotegrast In Lung Fibrosis Study ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
News headline image
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis – Could GRI-0621 Be The Solution? ↗
Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is unknown, but... 
Via Benzinga
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis
Follows positive data from INTEGRIS-IPF Phase 2a trial 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitis 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 ↗
 
Via Benzinga
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
First Republic Bank, Top Financial And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded lower, with the Nasdaq falling around 17 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
US Stocks Rise; Norwegian Cruise Line Posts Q1 Results ↗
U.S. stocks traded higher this morning, ahead of the Federal Reserve’s monetary policy meeting. Following the market opening Monday, the Dow traded up 0.15% to 34,147.97, while the NASDAQ inched up... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >